Concomitant use of an oral contraceptive with GLP1 agonist drugs (whether used for weight loss or type 2 diabetes) is going to be an increasingly common scenario and one we need to be mindful of
Jesinkey SR, Funk JA, Stallons LJ, Wills LP, Megyesi JK, Beeson CC, et al
Here is what each tier costs at Perfect B: Single-peptide protocol: $445 per cycle
STEP-2 (N=1,210 adults with type 2 diabetes) confirmed that even the 1.0 mg dose of semaglutide produces clinically significant metabolic changes within 8-12 weeks, which is well within the timeframe that ovulatory function may normalize in previously anovulatory women
In humans, insulin-like growth factor type 1 (IGF-1) and several of its binding proteins are positively associated with acquisition of PBM and the maintenance of bone mineral density (BMD) (911) and low IGF-1 levels have been found to be a risk factor for osteoporosis and fracture risk (3,1219)
This evolution in treatment highlights an urgent need for evidence that moves beyond weight loss alone to examine long-term cardiometabolic health, quality of life, and durability of treatment effects. Concerns about youth on GLP-1 According to Messiah, GLP-1 medications have demonstrated meaningful benefits for adolescents living with obesity, including substantial weight reduction and improvements in obesity-related conditions such as type 2 diabetes and hypertension, but she underscores that drugs need to be prescribed appropriately and accompanied by ongoing medical supervision